Clinical Trials

1,314 enrolled

Prostatic Neoplasms

NCT06520345 2026-05-27

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

520 enrolled

Prostatic Neoplasms

NCT07028853 2026-05-22

MEVPRO-3

1,000 enrolled

Prostatic Neoplasms

NCT01885949 2026-05-20

Tivozanib + Enzalutamide in Adv Prostate Cancer

Phase 2 Terminated

5 enrolled 8 charts

Phase 2 Not yet recruiting

Neoplasm Metastasis, Prostatic Neoplasms

NCT07592910 2026-05-18

MOMENT

60 enrolled

Adenocarcinoma, Prostatic Neoplasms

NCT03437941 2026-05-15

Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Terminated

39 enrolled 43 charts

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT05730712 2026-05-15

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

Phase 2 Completed

7 enrolled 10 charts

Prostatic Neoplasms

NCT06691984 2026-05-15

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

707 enrolled

Neoplasms, Prostatic Neoplasms

NCT02312557 2026-05-14

Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

58 enrolled 13 charts

Prostatic Neoplasms

NCT03644303 2026-05-14

TRAP

Phase NA Completed

86 enrolled 27 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT04262154 2026-05-11

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

28 enrolled 9 charts

Phase 1/2 Enrolling by invitation

Prostatic Neoplasms

NCT04145375 2026-05-08

Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol

40 enrolled

Prostatic Neoplasms

NCT04221542 2026-05-08

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 1 Recruiting

479 enrolled

Bites and Stings, Prostatic Neoplasms

NCT06632977 2026-05-08

PREDICT

474 enrolled

Prostatic Neoplasms

NCT02319837 2026-05-07

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

1,068 enrolled 20 charts 1 FDA

Prostatic Neoplasms

NCT02446444 2026-05-06

ENZARAD

802 enrolled

Prostatic Neoplasms

NCT03123978 2026-05-06

Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer

Phase 1 Completed

6 enrolled

Prostatic Neoplasms

NCT06764485 2026-05-06

rechARge

960 enrolled

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT07570979 2026-05-06

A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

Phase 1 Recruiting

208 enrolled

Prostatic Neoplasms

NCT05873192 2026-05-05

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

30 enrolled

Prostatic Neoplasms

NCT06551324 2026-05-05

MEVPRO-1

600 enrolled

Prostatic Neoplasms, Recurrence

NCT06616155 2026-05-05

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Recruiting

20 enrolled

Prostatic Neoplasms

NCT07181122 2026-04-28

PRO-MIND

Recruiting

102 enrolled

Depression, Fatigue, Sleep Initiation and Maintenance Disorders, Prostatic Neoplasms

NCT06844383 2026-04-24

TALENT

126 enrolled

Adenocarcinoma, Prostatic Neoplasms

NCT02555189 2026-04-22

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

Phase 1/2 Terminated

52 enrolled 31 charts

Prostatic Neoplasms

NCT05997615 2026-04-20

AMX-500

Phase 1 Recruiting

390 enrolled

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT06378866 2026-04-20

DIVINE

532 enrolled

Prostatic Neoplasms

NCT06592924 2026-04-14

TRIPLE-SWITCH

830 enrolled

Adenocarcinoma, Prostatic Neoplasms

NCT02225704 2026-04-13

Radium-223 in Combination With Enzalutamide

Phase 2 Completed

45 enrolled

Prostatic Neoplasms

NCT02960022 2026-04-13

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

900 enrolled

Prostatic Neoplasms

NCT03869762 2026-04-13

DICE

Phase 2 Terminated

7 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT07406282 2026-04-09

Double-DARE

Recruiting

1,400 enrolled

Prostatic Neoplasms

NCT04787744 2026-04-08

VA STARPORT

Phase 2/3 Recruiting

464 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT04821622 2026-04-07

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

599 enrolled

Prostatic Neoplasms

NCT06734130 2026-04-01

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

25 enrolled

Prostatic Neoplasms

NCT03674814 2026-03-31

Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

Phase 1 Completed

42 enrolled

Prostatic Neoplasms

NCT06096870 2026-03-25

Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy

65 enrolled

Prostatic Neoplasms

NCT06457919 2026-03-24

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

Phase 1/2 Recruiting

50 enrolled

Prostatic Neoplasms

NCT07428642 2026-03-18

PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.

Completed

168 enrolled

Prostatic Neoplasms

NCT05751941 2026-03-16

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

26 enrolled

Prostatic Neoplasms

NCT04179864 2026-03-10

CELLO-1

Phase 1/2 Terminated

102 enrolled 39 charts

Prostatic Neoplasms

NCT05726292 2026-03-04

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

90 enrolled

Prostatic Neoplasms

NCT07230106 2026-03-03

A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

218 enrolled

Prostatic Neoplasms

NCT05700903 2026-03-02

ARCH

Phase 4 Completed

10 enrolled

Hypertension, Kidney Diseases, Prostatic Neoplasms, Primary Dysautonomias

NCT03344211 2026-02-27

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

30 enrolled

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT02522715 2026-02-24

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

37 enrolled 10 charts

Phase 4 Active not recruiting

Prostatic Neoplasms

NCT03016741 2026-02-24

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

100 enrolled

Dementia, Prostatic Neoplasms, Cognitive Dysfunction, Prostatic Neoplasms, Castration-Resistant

NCT06855277 2026-02-24

AcTFirst

940 enrolled

Prostatic Neoplasms

NCT06236139 2026-02-17

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Recruiting

48 enrolled